What's new in obstetric anesthesia? Focus on preeclampsia

International Journal of Obstetric Anesthesia

Volumn 24, Issue 3, 2015, Pages 264-271

  Leffert, L R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; GLYCERYL TRINITRATE; REMIFENTANIL;

ANESTHESIOLOGICAL PROCEDURE; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CESAREAN SECTION; COMORBIDITY; DELIVERY; DISEASE CONTROL; EPIDURAL ANESTHESIA; FEMALE; FIBRINOLYSIS; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HYPERTENSION; OBSTETRIC ANALGESIA; OBSTETRIC ANESTHESIA; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREECLAMPSIA; PREVALENCE; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPINAL ANESTHESIA; THROMBOCYTE COUNT; PRE-ECLAMPSIA; PREGNANCY; PROCEDURES;

ANESTHESIA, OBSTETRICAL; COMORBIDITY; FEMALE; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC; PRE-ECLAMPSIA; PREGNANCY;

EID: 84942987267     PISSN: 0959289X     EISSN: 15323374     Source Type: Journal    
DOI: 10.1016/j.ijoa.2015.03.008     Document Type: Review

References (61)

1. Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol 2013;170:1-7.
2. Ananth CV, Keyes KM, Wapner RJ. Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis. BMJ 2013;347:f6564.
3. Kuklina EV, Ayala C, Callaghan WM. Hypertensive disorders and severe obstetric morbidity in the United States. Obstet Gynecol 2009;113:1299-306.
4. Main EK, McCain CL, Morton CH, Holtby S, Lawton ES. Pregnancy-related mortality in California: causes, characteristics, and improvement opportunities. Obstet Gynecol 2015; Publish Ahead of Print:10.1097/aog.0000000000000746.
5. World Health Organization (WHO). WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. Geneva (Switzerland): World Health Organization (WHO), 2011. [accessed March 2015].
6. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Preg Hypertens 2014;4:105-45.
7. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on hypertension in pregnancy. Obstet Gynecol 2013;122:1122-31.
8. National Collaborating Centre for Women's and Children's Health. Hypertension in pregnancy. The management of hypertensive disorders during pregnancy. London (UK): National Institute for Health and Clinical Excellence. 2010. NICE guidelines [CG107]. [accessed March 2015].
9. Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am J Obstet Gynecol 2013;209:544.e1-544.e12.
10. Kucukgoz Gulec U, Ozgunen FT, Buyukkurt S, et al. Comparison of clinical and laboratory findings in early- and late-onset preeclampsia. J Matern Fetal Neonatal Med 2013;26:1228-33.
11. Robillard P-Y, Dekker G, Chaouat G. Fourteen years of debate and workshops on the immunology of preeclampsia. Where are we now after the 2012 workshop? J Reprod Immunol 2014;101-102:62-9.
12. Ahmed A. New insights into the etiology of preeclampsia: identification of key elusive factors for the vascular complications. Thromb Res 2011;127:S72-5.
13. Bello N, Rendon IS, Arany Z. The relationship between preeclampsia and peripartum cardiomyopathy: a systematic review and meta-analysis. J Am Coll Cardiol 2013;62:1715-23.
14. Chaiworapongsa T, Romero R, Korzeniewski SJ, et al. Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia. Am J Obstet Gynecol 2013;208:287.e1-287.e15.
15. Chaiworapongsa T, Romero R, Korzeniewski SJ, et al. Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study. J Matern Fetal Neonatal Med 2013;27:132-44.
16. De Oliveira L, Peraçoli JC, Peraçoli MT, et al. Sflt-1/plgf ratio as a prognostic marker of adverse outcomes in women with earlyonset preeclampsia. Preg Hypertens 2013;3:191-5.
17. Chappell LC, Duckworth S, Seed PT, et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation 2013;128:2121-31.
18. von Dadelszen P, Magee L. Pre-eclampsia: an update. Curr Hypertens Rep 2014;16:1-14.
19. Benton SJ, Hu Y, Xie F, et al. Can placental growth factor in maternal circulation identify fetuses with placental intrauterine growth restriction? Am J Obstet Gynecol 2012;206:163.e1-7.
20. Buurma A, Turner R, Driessen J, et al. Genetic variants in preeclampsia: a meta-analysis. Hum Reprod Update 2013;19:289-303.
21. Luizon MR, Sandrim VC. Pharmacogenomic approaches that may guide preeclampsia therapy. Pharmacogenomics 2013;14:591-3.
22. Sandrim VC, Palei AC, Luizon MR, et al. eNOS haplotypes affect the responsiveness to antihypertensive therapy in preeclampsia but not in gestational hypertension. Pharmacogenomics J 2009;10: 40-5.
23. Leffert LR, Clancy CR, Bateman BT, Bryant AS, Kuklina EV. Hypertensive disorders and pregnancy-related stroke: frequency, trends, risk factors, and outcomes. Obstet Gynecol 2015;125: 124-31.
24. Wiegman MJ, Zeeman GG, Aukes AM, et al. Regional distribution of cerebral white matter lesions years after preeclampsia and eclampsia. Obstet Gynecol 2014;123:790-5.
25. Ghossein-Doha C, Peeters L, van Heijster S, et al. Hypertension after preeclampsia is preceded by changes in cardiac structure and function. Hypertension 2013;62:382-90.
26. Männistö T, Mendola P, Vääräsmäki M, et al. Elevated blood pressure in pregnancy and subsequent chronic disease risk. Circulation 2013;127:681-90.
27. Thangaratinam S, Langenveld J, Mol BW, Khan KS. Prediction and primary prevention of pre-eclampsia. Best Pract Res Clin Obstet Gynaecol 2011;25:419-33.
28. Bushnell C, McCullough LD, Awad IA, et al. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014;45:1545-88.
29. Le Fevre ML. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive services task force recommendation statement. Ann Inter Med 2014;161:819-26.
30. Rodger MA, Carrier M, Le Gal G, et al. Meta-analysis of low molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications. Blood 2013;123:822-8.
31. Duley L, Meher S, Jones L. Drugs for treatment of very high blood pressure during pregnancy (review). Cochrane Database Syst Rev 2013;7:CD001449.
32. Shekhar S, Sharma C, Thakur S, Verma S. Oral nifedipine or intravenous labetalol for hypertensive emergency in pregnancy: a randomized controlled trial. Obstet Gynecol 2013;122:1057-63.
33. Martin JN, Thigpen BD, Moore RC, et al. Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure. Obstet Gynecol 2005;105:246-54.
34. Foo L, Bewley S, Rudd A. Maternal death from stroke: a thirty year national retrospective review. Eur J Obstet Gynecol Reprod Biol 2013;171:266-70.
35. van Veen TR, Panerai RB, Haeri S, et al. Cerebral autoregulation in normal pregnancy and preeclampsia. Obstet Gynecol 2013;122:1064-9.
36. Westhoff-Bleck M, Podewski E, Hilfiker A, Hilfiker-Kleiner D. Cardiovascular disorders in pregnancy: diagnosis and management. Best Pract Res Clin Obstet Gynaecol 2013;27:821-34.
37. Yakoob MY, Bateman BT, Ho E, et al. The risk of congenital malformations associated with exposure to b-blockers early in pregnancy: a meta-analysis. Hypertension 2013;62:375-81.
38. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk: Lippincott Williams & Wilkins; 2012.
39. Orbach H, Matok I, Gorodischer R, et al. Hypertension and antihypertensive drugs in pregnancy and perinatal outcomes. Am J Obstet Gynecol 2013;208:301.e1-6.
40. Macones GA, Odibo A, Cahill A, et al. Discussion: hypertension and antihypertensives in pregnancy. Am J Obstet Gynecol: 208.e1-2.
41. Koren G. Systematic review of the effects of maternal hypertension in pregnancy and antihypertensive therapies on child neurocognitive development. Reprod Toxicol 2013;39:1-5.
42. Bateman BT, Huybrechts KF, Fischer MA, et al. Chronic hypertension in pregnancy and the risk of congenital malformations: a cohort study. Am J Obstet Gynecol 2015;212: 337.e1-337.e14.
43. Magee LA, von Dadelszen P, Rey E, et al. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med 2015;372:407-17.
44. Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension 2005;46:500-7.
45. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs. placebo on Alzheimer disease progression: a randomized controlled trial. J Am Med Assoc 2003;289: 2819-26.
46. Wasden SW, Ragsdale ES, Chasen ST, Skupski DW. Impact of non-steroidal anti-inflammatory drugs on hypertensive disorders of pregnancy. Preg Hypertens 2014;4:259-63.
47. Churchill D, Duley L, Thornton J, Jones L. Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks' gestation. Cochrane Database Syst Rev 2013;7:CD003106.
48. American College of Obstetricians and Gynecologists. Practice bulletins no. 139: premature rupture of membranes. Obstet Gynecol 2013;122:918-30.
49. Vigil-De Gracia P, Reyes Tejada O, Calle Miñaca A, et al. Expectant management of severe preeclampsia remote from term: the MEXPRE Latin study, a randomized, multicenter clinical trial. Am J Obstet Gynecol 2013;209:425.e1-8.
50. Bateman BT, Mhyre JM, Ehrenfeld J, et al. The risk and outcomes of epidural hematomas after perioperative and obstetric epidural catheterization: a report from the multicenter perioperative outcomes group research consortium. Anesth Analg 2013;116:1380-5.
51. D'Angelo R, Smiley RM, Riley ET, Segal S. Serious complications related to obstetric anesthesia: the serious complication repository project of the society for obstetric anesthesia and perinatology. Anesthesiology 2014;120:1505-12.
52. Van Veen JJ, Nokes TJ, Makris M. The risk of spinal haematoma following neuraxial anaesthesia or lumbar puncture in thrombocytopenic individuals. Br J Haematol 2010;148:15-25.
53. Orlikowski CE, Rocke DA, Murray WB, et al. Thrombelastography changes in pre-eclampsia and eclampsia. Br J Anaesth 1996;77:157-61.
54. Dennis AT. Management of pre-eclampsia: issues for anaesthetists. Anaesthesia 2012;67:1009-20.
55. Davies JR, Fernando R, Hallworth SP. Hemostatic function in healthy pregnant and preeclamptic women: an assessment using the platelet function analyzer (PFA-100) and thromboelastograph. Anesth Analg 2007;104:416-20.
56. Henke VG, Bateman BT, Leffert LR. Spinal anesthesia in severe preeclampsia. Anesth Analg 2013;117:686-93.
57. Saha D, Ghosh S, Bhattacharyya S, et al. Comparison of hemodynamic response and vasopressor requirement following spinal anaesthesia between normotensive and severe preeclamptic women undergoing caesarean section: a prospective study. J Obstet Anaesth Crit Care 2013;3:23-6.
58. Yoo KY, Kang DH, Jeong H, et al. A dose-response study of remifentanil for attenuation of the hypertensive response to laryngoscopy and tracheal intubation in severely preeclamptic women undergoing caesarean delivery under general anaesthesia. Int J Obstet Anaesth 2013;22:10-8.
59. Pant M, Fong R, Scavone B. Prevention of peri-induction hypertension in preeclamptic patients: a focused review. Anesth Analg 2014;119:1350-6.
60. Ahmed R, Dunford J, Mehran R, Robson S, Kunadian V. Preeclampsia and future cardiovascular risk among women: a review. J Am Coll Cardiol 2014;63:1815-22.
61. Berks D, Hoedjes M, Raat H, et al. Risk of cardiovascular disease after pre-eclampsia and the effect of lifestyle interventions: a literature-based study. BJOG 2013;120:924-31.